TMCnet News

Research and Markets: Opioid Induced Bowel Dysfunction Pipeline Insights 2015
[January 27, 2015]

Research and Markets: Opioid Induced Bowel Dysfunction Pipeline Insights 2015


Research and Markets (http://www.researchandmarkets.com/research/7bn87b/opioid_induced) has announced the addition of the "Opioid Induced Bowel Dysfunction-Pipeline Insights, 2014" subscription to their offering.

This Opioid Induced Bowel Dysfunction-Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Opioid Induced Bowel Dysfunction.

This report provides information on the therapeutic development based on the Opioid Induced Bowel Dysfunction dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery andunknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.



The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:


  1. Opioid Induced Bowel Dysfunction Overview
  2. Opioid Induced Bowel Dysfunction Pipeline Therapeutics
  3. Opioid Induced Bowel Dysfunction Therapeutics under Development by Companies
  4. Opioid Induced Bowel Dysfunction Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Opioid Induced Bowel Dysfunction Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Opioid Induced Bowel Dysfunction Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Opioid Induced Bowel Dysfunction Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Opioid Induced Bowel Dysfunction - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Opioid Induced Bowel Dysfunction - Discontinued Products
  19. Opioid Induced Bowel Dysfunction - Dormant Products
  20. Companies Involved in Therapeutics Development for Opioid Induced Bowel Dysfunction
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/7bn87b/opioid_induced


[ Back To TMCnet.com's Homepage ]